company background image
MTNB logo

Matinas BioPharma Holdings NYSEAM:MTNB Stock Report

Last Price

US$0.29

Market Cap

US$63.0m

7D

0.7%

1Y

-36.2%

Updated

27 Mar, 2024

Data

Company Financials +

Matinas BioPharma Holdings, Inc.

NYSEAM:MTNB Stock Report

Market Cap: US$63.0m

MTNB Stock Overview

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates.

MTNB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Matinas BioPharma Holdings, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Matinas BioPharma Holdings
Historical stock prices
Current Share PriceUS$0.29
52 Week HighUS$0.89
52 Week LowUS$0.11
Beta1.53
1 Month Change7.77%
3 Month Change27.99%
1 Year Change-36.22%
3 Year Change-72.39%
5 Year Change-73.65%
Change since IPO-77.70%

Recent News & Updates

Recent updates

Here's Why We're Not Too Worried About Matinas BioPharma Holdings' (NYSEMKT:MTNB) Cash Burn Situation

Feb 23
Here's Why We're Not Too Worried About Matinas BioPharma Holdings' (NYSEMKT:MTNB) Cash Burn Situation

Shareholder Returns

MTNBUS BiotechsUS Market
7D0.7%-0.5%0.6%
1Y-36.2%9.6%29.5%

Return vs Industry: MTNB underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: MTNB underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is MTNB's price volatile compared to industry and market?
MTNB volatility
MTNB Average Weekly Movement12.1%
Biotechs Industry Average Movement11.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: MTNB's share price has been volatile over the past 3 months.

Volatility Over Time: MTNB's weekly volatility has decreased from 48% to 12% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201334Jerry Jabbourhttps://www.matinasbiopharma.com

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.

Matinas BioPharma Holdings, Inc. Fundamentals Summary

How do Matinas BioPharma Holdings's earnings and revenue compare to its market cap?
MTNB fundamental statistics
Market capUS$62.98m
Earnings (TTM)-US$21.26m
Revenue (TTM)US$2.16m

29.2x

P/S Ratio

-3.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MTNB income statement (TTM)
RevenueUS$2.16m
Cost of RevenueUS$14.69m
Gross Profit-US$12.53m
Other ExpensesUS$8.73m
Earnings-US$21.26m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.098
Gross Margin-580.45%
Net Profit Margin-984.81%
Debt/Equity Ratio0%

How did MTNB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.